Tesamorelin Dosage: The Regimens Studied in the Trials

The short version

Here is the tesamorelin dosage picture from the studies, in plain terms — and a clear boundary first: this page reports what researchers administered, never what anyone should take. In the pivotal trials, the dose was 2 mg injected under the skin once a day. The peptide leaves the blood quickly (within the hour), but the IGF-1 growth signal it switches on stays up all day, which is why once-daily dosing was enough. There are no human dosing instructions here — only the regimens the published literature documents, each cited to its source.

The studied dose: 2 mg/day subcutaneous

The regimen used in both pivotal Phase 3 trials, and the FDA-approved dose, was 2 mg administered subcutaneously once daily ^[1][2]. The 26-week NEJM trial and the 52-week program both used this dose ^[1][2]. A lower 1 mg arm was studied in the 12-week dose-ranging trial, where it produced a smaller IGF-I rise (+48% versus +65% at 2 mg), establishing the dose-response relationship ^[8].

To be explicit about framing: these are doses administered to participants in clinical trials — "studied at 2 mg/day in HIV patients" — not a recommendation for any individual. The approved product is a prescription drug for a specific HIV indication; research-grade tesamorelin is supplied for laboratory research and is not approved for general human self-administration ^[5].

Route of administration

Subcutaneous injection at an abdominal site is the only route studied in clinical trials and the only FDA-approved route ^[1][14]. There is no published oral, intranasal, or other-route efficacy data for tesamorelin — the peptide would not survive oral digestion, which is true of GHRH analogues generally. Every efficacy figure on this site derives from once-daily subcutaneous administration ^[1][2][3].

Half-life and pharmacokinetics

Tesamorelin's pharmacokinetics are the reason a short-lived peptide works on a once-daily schedule. Population PK modeling reported apparent plasma clearance of approximately 1,060 L/h, with no clinically relevant demographic covariates and roughly a 13% increase in absorbed fraction by day 14 versus day 1 ^[16]. Secondary sources, including the FDA label, place the terminal half-life on the order of 26-38 minutes ^[14].

Despite that rapid clearance, the downstream IGF-1 elevation persists across the dosing interval — the biological effect outlasts the molecule, which is the pharmacologic basis for once-daily dosing ^[16]. This split between a short plasma half-life and a sustained downstream effect is a recurring theme in the GHRH-analogue literature.

Formulation and stability

Stability is engineered into the molecule and the formulation. The trans-3-hexenoic acid modification on the N-terminus blocks the DPP-IV cleavage that rapidly inactivates native GHRH, extending the peptide's biological activity ^[6]. The clinical product is supplied as a lyophilized (freeze-dried) powder that requires reconstitution before subcutaneous injection; the FDA label specifies refrigerated storage and use of the reconstituted solution within a defined window ^[14]. These handling facts are reported here as documented product characteristics, not as preparation instructions.

Duration in the trials

Trial durations defined what was measured. Significant visceral-fat reduction appeared at 26 weeks in the pivotal RCTs and was sustained at roughly -18% over 52 weeks of continued dosing ^[1][2]. The dose-ranging study ran 12 weeks ^[8], and the JAMA liver-fat trial ran 6 months ^[3]. Across the program, the effect was contingent on continued administration — visceral fat reaccumulated within weeks of stopping ^[2]. There is no studied "cycle" or tapering schedule in the human literature beyond continuous once-daily dosing.